This drug is a novel single-entity tablet, combining a dihydropyridine calcium channel blocker and an angiotensin receptor blocker.
Alka Patel, RPh, PharmD
Advertisement
Articles by Alka Patel, RPh, PharmD
Ms. Domenici and Dr. Patel are both pharmacists at Brigham and Women's Hospital, Boston, Mass.
Ms. Domenici and Dr. Patel are both pharmacists at Brigham and Women's Hospital, Boston, Mass.
Ms. Domenici and Dr. Patel are both pharmacists at Brigham and Women's Hospital, Boston, Mass. Ms. Aiello is a sixth-year PharmD candidate from Massachusetts College of Pharmacy currently on clinical clerkship in the Investigational Drug Service at Brigham and Women's Hospital.
Advertisement
Latest Updated Articles
- Rx Product News: Profile: A Closer Look at New FDA Actions: Exforge
Published: November 1st 2007 | Updated:
- A closer look at new FDA actions: Shire's Vyavanse
Published: September 1st 2007 | Updated:
- A closer look at new FDA actions: Merck & Co's Janumet
Published: August 1st 2007 | Updated:
- A closer look at new FDA actions
Published: July 1st 2007 | Updated:
- AstraZeneca's Seroquel
Published: June 1st 2007 | Updated:
- GlaxoSmithKline Consumer Healthcare's alli
Published: June 1st 2007 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer
2
Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer
3
Cholesterol-HDL-Glucose Index Linked to Type 2 Diabetes Prevalence in Adults
4
Under Pressure: A Brief Overview of the Updated Hypertension Guidelines
5
